Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06604897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06604897 · ClinicalTrials.gov record · last posted 2026-08-14

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

StatusCompleted
PhaseNot specified
Started2023-01-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of general practices, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities, etc.

Protocol amendment history 4 changes detected by DataLookout

2026-08-15
Trial completed
2026-08-15
Sponsor changed: Novartis → Novartis Pharmaceuticals
WasNovartis
NowNovartis Pharmaceuticals
2026-08-15
Primary completion pushed: 2025-03-31 → 2025-10-31
2026-08-15
Completion pushed: 2025-03-31 → 2025-10-31
Trial Details
NCT Number NCT06604897
Lead Sponsor Novartis Pharmaceuticals
Conditions Essential Hypertension
Enrollment 1,405 participants
Start Date 2023-01-31
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14